A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

This pregnancy registry study is tracking outcomes for women with multiple sclerosis (MS) who became pregnant while taking or after taking BRIUMVI (ublituximab), to understand how the drug affects pregnancy and newborn health. **You may be eligible if...** - You have a diagnosis of multiple sclerosis - You are currently pregnant or have recently been pregnant (within the past year) - Either you were exposed to at least one dose of BRIUMVI at any point (exposed group), OR you have never taken BRIUMVI during pregnancy (comparison group) - Your healthcare provider has authorized sharing your data with the registry **You may NOT be eligible if...** - You were exposed to anti-CD20 antibody drugs (a class of MS medications including BRIUMVI) at any point during the current pregnancy before joining — if enrolling in the unexposed group - Your pregnancy already ended before you first contacted the study team (retrospective enrollment) - You were exposed to medications known to harm the fetus or other experimental drugs during pregnancy Talk to your doctor to see if this trial is right for you.